"Prostatic acid phosphatase (PAP) was the first clinically useful tumour marker after its first description by AB Gutman and EB Gutman in 1938 4. After the appearance of prostate-specific antigen (PSA) in the 1980s, its use as a serum marker declined considerably."
"Prostatic acid phosphatase (PAP) was the first clinically useful tumour marker after its first description by AB Gutman and EB Gutman in 1938 4. After the appearance of prostate-specific antigen (PSA) in the 1980s, its use as a serum marker declined considerably."
"It might also be positive in other cancers, including bladder adenocarcinoma, rectal neuroendocrine tumours, or salivary gland tumours, and diverse nonprostatic diseases such as Paget disease, hyperparathyroidism, multiple myeloma, etc. 2."